Keywords
Toxoplasmosis
immunosuppression therapy
How to Cite
Abstract
Objectives: The purpose of the study was to determine the seroprevalence of Toxoplasma gondii infection and to describe the clinical characteristics of lupus activity in patients with Systemic Lupus Erythematosus whose samples were stored in an autoimmune disease biobank and were collected between 2013 and 2015.
Methodology: A retrospective, cross-sectional study was conducted in patients with SLE. Demographic and clinical data were collected from patient charts. Qualitative and quantitative measurement of IgG anti-Toxoplasma gondii antibodies was performed.
Results: The study included 106 patients with SLE, 88.68% female, with a median age of 31.00 years (RI: 24 - 59). The seroprevalence of toxoplasmosis was 72.64%. The most frequently used immunosuppressive treatment was Hydroxychloroquine and the majority (76.19%) used a combination of drugs.
Conclusion: The seroprevalence of toxoplasmosis was determined in the study populati on, and the result was close to the upper limit of the range reported in studies performed in rheumatologic patients. This shows the importance of carrying out further research in similar populations and of including the determination of IgG anti-T. gondii antibodies in the routine studies performed in these patients.
References
(1) Galeano L, Morel Ayala Z, Campuzano de Rolón A. Juvenile Systemic LupusErythematosusandhematologicalcompromise.RevParaguaya Reumatol. 2020;6(1):5–10. DOI: https://doi.org/10.18004/rpr/2020.06.01.5-10
(2) Acosta Colmán I, Avila G, Acosta ME, Aquino A, Centurión O, Duarte M. Clinical and laboratory manifstations in Systemic Lupus Erythema- tosus. Memorias del Inst Investig en Ciencias la Salud. 2016;14(1): 94–104. DOI: https://doi.org/10.18004/mem.iics/1812-9528/2016.014(01)94-109
(3) Vázquez MA, Rojas E, Losanto J, Bauman K, Acosta ME, Avila G, et al. Características y clínico-epidemiológicas de los pacientes de la cohorte Lupus Paraguay (2013-2014). Memorias del Inst Investig en Ciencias la Salud. 2019;17(1):69–74. DOI: https://doi.org/iics/1812-9528/2019.017(01)69-074
(4) Villalobos Zúñiga MA. Enfermedades Infecciosas En Pacientes Con Lupus Eritematoso Sistémico En El Hospital Calderón Guardia: Caracterización, Incidencia, Profilaxis Y Factores Asociados. Rev Clínica Esc Med UCR-HSJD. 2011;2(4):21–34. DOI: https://doi.org/10.15517/rc_ucr-hsjd.v2i4.6524
(5) Alarcón GS. Infections in Systemic Connective Tissue Diseases: Systemic Lupus Erythematosus, Scleroderma, and Polymyositis/ Dermatomyositis. Infect Dis Clin North Am. 2006;20(4):849–75. DOI: https://doi.org/10.1016/j.idc.2006.09.007
(6) AD, Mudinutti C, De Freitas Peigo M, Leon LL, Costallat LTL, Rossi CL, et al. Active human herpesvirus infections in adults with systemic lupus erythematosus and correlation with the SLEDAI score.AdvRheumatol.2020;60(1). DOI: https://doi.org/10.1186/s42358-020-00144-6
(7) Oke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):1–11. DOI: https://doi.org/10.1186/s13075-019-1878-y
(8) Furuya H, Ikeda K, Iida K, Suzuki K, Furuta S, Tamachi T, et al. Disseminated toxoplasmosis with atypical symptoms which developed with exacerbation of systemic lupus erythematosus. Lupus. 2019;28(1):133–6. DOI: https://doi.org/10.1177/0961203318815583
(9) Zhang J, Qin X, Zhu Y, Zhang S, Zhang XW, Lu H. Mechanism of dexamethasone in the context of Toxoplasma gondii infection. Parasitology. 2017;144(11):1551–9. DOI: https://doi.org/10.1017/S0031182017001111
(10) Melgarejo P, Cabrera N, Ovando F, Avila-Pedretti G. Seroprevalencia de chagas y toxoplasmosis en pacientes con enfermedades reumatológicas. Informe preliminar. Rev Paraguaya Reumatol. 2020;6(2):79–84. DOI: https://doi.org/10.18004/rpr/2020.06.02.79-84
(11) Wilcox MH, Powell RJ, Pugh SF, Balfour AH. Toxoplasmosis and systemic lupus erythematosus. Ann Rheum Dis. 1990;49(4):254– 7. DOI: https://doi.org/10.1136/ard.49.4.254
(12) Santoscoy G, Nicola G, Montoya H, Muñoz C, Santoscoy A, Santoscoy LA. Valores de referencia de anticuerpos anti Toxoplasma gondii IgG e IGM en sangre [Internet]. Unidad de Patología Clínica. 2021. Available from: https://upc.com.mx/examenes/v/130
(13) Montoya MT, Gomez JE, Castaño JC, Marx C, Aubert D, Bonhomme A, et al. Avances diagnósticos en Toxoplasmosis. Acta Médica Colomb. 1996;21:127–38.
(14) Bobić B, Villena I, Stillwaggon E. Prevention and mitigation of congenital toxoplasmosis. Economic costs and benefits in diverse settings. Food Waterborne Parasitol. 2019;16:1–11. DOI: https://doi.org/10.1016/j.fawpar.2019.e00058
(15) Romero DA, González-Vatteone C, Guillen I de, Aria L, Meza T, Rojas A, et al. Seroprevalence and associated risk factors of toxoplasmosis among women in reproductive age who attended district Hospital of Lambaré, Paraguay. Memorias del Inst Investig en Ciencias la Salud. 2018;15(3):83–8. DOI: https://doi.org/10.18004/mem.iics/1812-9528/2017.015(03)83-088
(16) Tian AL, Gu YL, Zhou N, Cong W, Li GX, Elsheikha HM, et al. Seroprevalence of Toxoplasma gondii infection in arthritis patients in eastern China. Infect Dis poverty. 2017;6(1):153. DOI: https://doi.org/10.1186/ s40249-017-0367-2
(17) Fischer S, Yinon NA. Toxoplasma gondii : bystander or cofactor in rheumatoid arthritis. Immunol Res. 2013;56:287–92. DOI: https://doi.org/10.1007/s12026-013-8402-2
(18) Ariza K, Isaza P, Gaviria AM, Quiceno JM, Vinaccia S, Alvarán L, et al. Calidad de vida relacionada con la salud, factores psicológicos y fisiopatológicos en pacientes con diagnóstico de lupus eritematoso sistémico -LES. [Health-related quality of life, psychological and pathophysiological factors in patients with diagnosis o. Ter Psicológica. 2010;28(1):27–36. DOI: https://doi.org/10.4067/S0718-48082010000100003.
(19) Fontclara L, Bianco H. Factores de riesgo de mortalidad en Pacientes Con Lupus Eritematoso Cuidados Intensivos. Rev Paraguaya Reumatol. 2015;1(2):99–107.
(20) Enberg G. M, Kahn C. M, Goity F. C, Villalón S. MV, Zamorano R. J, Figueroa E. F. Infecciones en pacientes con lupus eritematoso sistémico. Rev Med Chil. 2009;137(10):1367–74. DOI: https://doi.org/10.4067/s0034-98872009001000014
(21) Romero-Moreno JR, sa Ramírez-Villafaña M, la González-Ponce F, ra González-López L. Síndrome metabólico en lupus eritematoso sistémico. El Resid. 2014;9(3):116–23.
(22) Cabral M, Carpinelli M, Giménez V, Rovira C, Ferreira L. Perfil inmunológico, enfermedades infecciosas y no infecciosas en un grupo de pacientes paraguayos con lupus eritematoso sistémico(LES). Memorias del Inst Investig en Ciencias la Salud. 2007;5(2):6–10.